<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05012202</url>
  </required_header>
  <id_info>
    <org_study_id>21-0123</org_study_id>
    <nct_id>NCT05012202</nct_id>
  </id_info>
  <brief_title>Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women</brief_title>
  <official_title>Validating a New Point-of-care Device for Estimation of Blood Count in Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postpartum hemorrhage is a well-known complication of delivery and the leading cause of&#xD;
      maternal mortality worldwide. In developed nations, a complete blood count (CBC) is commonly&#xD;
      collected as a means to assess or base treatment for blood loss. The Hemi device is a&#xD;
      point-of-care device designed to provide hematocrit, followed by the stage of hemorrhagic&#xD;
      shock using artificial intelligence algorithms. The ultimate goal of the product is to&#xD;
      provide an accurate hematocrit from easily attainable samples such as vaginal blood during&#xD;
      hemorrhage to remove yet another barrier to access for actively bleeding women. The purpose&#xD;
      of this study is to compare the hematocrit of vaginal blood using the Hemi device with&#xD;
      standard venipuncture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective cohort study. The investigators will recruit 41 pregnant women&#xD;
      admitted for delivery. Following delivery, a sample of vaginal blood will be collected and&#xD;
      the Hemi device will be used to obtain hematocrit. These results will be masked to the&#xD;
      clinical team until the time of data collection. A CBC will also be collected via&#xD;
      venipuncture at this time. This study will be comparing hematocrit levels by standard&#xD;
      clinical laboratory versus results from the device.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>During delivery</time_frame>
    <description>Comparison of hematocrit from vaginal blood sample versus systemic sample</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to obtain results</measure>
    <time_frame>During delivery</time_frame>
    <description>Time to obtain hematocrit level results</description>
  </secondary_outcome>
  <enrollment type="Anticipated">41</enrollment>
  <condition>Blood Loss</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hemi device</intervention_name>
    <description>A sample of vaginal blood will be collected following delivery and analyzed by the device to provide a hematocrit level, which will be masked to the clinical team.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population includes pregnant women admitted to the Labor &amp; Delivery unit for&#xD;
        delivery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women between the ages of 18-50&#xD;
&#xD;
          -  Admission for vaginal delivery&#xD;
&#xD;
          -  Singleton pregnancy&#xD;
&#xD;
          -  Term gestation (&gt;=37 weeks)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant women &lt; 18 years or &gt; 50 years&#xD;
&#xD;
          -  Incarcerated patients&#xD;
&#xD;
          -  Patient unwilling or unable to provide consent&#xD;
&#xD;
          -  Enrolled in another trial that may affect outcome&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Marissa Berry, MD</last_name>
    <phone>4097474952</phone>
    <email>majberry@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Antonio F Saad, MD</last_name>
    <email>afsaad@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UTMB</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa J Berry, MD</last_name>
      <email>majberry@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Antonio F Saad, MD</last_name>
      <email>afsaad@utmb.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>August 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Medical Branch, Galveston</investigator_affiliation>
    <investigator_full_name>Marissa Berry</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Vaginal delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

